Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 17/20 | 0.38 |
| ▸ | NOS1 | P29475 | 13/20 | 0.38 |
| ▸ | NOS3 | P29474 | 11/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13828946 | 1.00 | NOS2 (0.38) | NOS2NOS1NOS3MEN1CYP2C19 | |
| SCHEMBL13828779 | 1.00 | NOS2 (0.38) | NOS2NOS1NOS3MEN1CYP2C19 | |
| SCHEMBL13828774 | 1.00 | NOS2 (0.38) | NOS2NOS1NOS3MEN1CYP2C19 | |
| SCHEMBL13829043 | 1.00 | NOS2 (0.38) | NOS2NOS1NOS3MEN1CYP2C19 | |
| SCHEMBL13829011 | 1.00 | NOS2 (0.38) | NOS2NOS1NOS3MEN1CYP2C19 | |
| SCHEMBL16155052 | 1.00 | NOS2 (0.38) | NOS2NOS1NOS3MEN1CYP2C19 | |
| SCHEMBL16155050 | 0.82 | FOLH1 (0.44) | NOS2NOS1NOS3SLC7A5 | |
| SCHEMBL1233077 | 0.79 | SLC7A5 (0.50) | NOS2NOS1NOS3KMT2ASLC7A5 | |
| SCHEMBL3813048 | 0.79 | SLC7A5 (0.50) | NOS2NOS1NOS3KMT2ASLC7A5 | |
| SCHEMBL12900073 | 0.79 | SLC7A5 (0.50) | NOS2NOS1NOS3KMT2ASLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120288444-A1 | SINGLE DIASTEREOMERS OF 4-FLUOROGLUTAMINE AND METHODS OF THEIR PREPARATION AND USE | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2012-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120288444-A1 | SINGLE DIASTEREOMERS OF 4-FLUOROGLUTAMINE AND METHODS OF THEIR PREPARATION AND USE | GCG, FPGS, FOLH1 | NOS2 4514/4885NOS1 4511/4885NOS3 4510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.